Monocytes are derived from hematopoietic stem cells through a series of intermediate progenitor stages, but the factors that regulate this process are incompletely defined. Using a Ccr2/Cx 3 cr1 dual-reporter system to model murine monocyte ontogeny, we conducted a small-molecule screen that identified an essential role of mechanistic target of rapamycin complex 1 (mTORC1) in the development of monocytes and other myeloid cells. Confirmatory studies using mice with inducible deletion of the mTORC1 component Raptor demonstrated absence of mature circulating monocytes, as well as disruption in neutrophil and dendritic cell development, reflecting arrest of terminal differentiation at the granulocyte-monocyte progenitor stage. Conversely, excess activation of mTORC1 through deletion of the mTORC1 inhibitor tuberous sclerosis complex 2 promoted spontaneous myeloid cell development and maturation. Inhibitor studies and stage-specific expression profiling identified failure to down-regulate the transcription factor Myc by the mTORC1 target ribosomal S6 kinase 1 (S6K1) as the mechanistic basis for disrupted myelopoiesis. Together, these findings define the mTORC1-S6K1-Myc pathway as a key checkpoint in terminal myeloid development.
INTRODUCTION
Monocytes are innate immune cells with pleiotropic functions, including cytokine production, pathogen clearance, antigen presentation, and wound healing (1) (2) (3) . Studies over the past two decades have delineated two major subsets of monocytes in mice and humans. Inflammatory monocytes, characterized by the high expression of the chemokine receptor Ccr2, are continuously released from the bone marrow into the circulation. These cells, alternatively known as classical monocytes, are Ly6C hi in mice and correspond to the CD14 hi CD16 lo monocyte subset in humans; they migrate to inflamed tissues where they may reside as tissue monocytes or differentiate into macrophages (3) (4) (5) . In contrast, patrolling monocytes represent a more differentiated subset and are marked by the higher surface expression of Cx 3 cr1. Patrolling monocytes express low levels of Ly6C in mice and are CD14 lo CD16
hi in humans; they survey the endothelium for evidence of inflammation or injury (6) . Adoptive transfer and fate-mapping studies support the hypothesis that monocytes develop along a differentiation continuum in which inflammatory monocytes give rise to the patrolling subset in the circulation (7, 8) .
Development of monocytes from bone marrow progenitors is a complex process that combines the regulated expression of numerous transcription factors, with influence by growth factors and cytokines (9) . Monocytes and neutrophils are both derived from hematopoietic stem cells (HSCs) via common myeloid progenitors (CMPs), but their differentiation bifurcates after the granulocyte-monocyte progenitor (GMP) stage (10) . GMPs give rise to monocyte-dendritic cell (DC) progenitors (MDPs) and the downstream common monocyte progenitors (CMoPs) that ultimately differentiate into Ly6C hi monocytes (11, 12) . The transcription factors Spi-1 (PU.1) interferon regulatory factor 8 (Irf8), and the downstream Kruppel-like factor 4 are critical for the production of Ly6C hi monocytes in mice (13) (14) (15) , whereas the orphan receptor Nr4a1 (nuclear receptor subfamily 4 group a member 1) and macrophage colony-stimulating factor (M-CSF) signaling are essential for the differentiation of Ly6C lo monocytes (16) . Evaluation of monocyte differentiation from myeloid progenitors is challenging because of the paucity of precursor cells and the potential complications introduced by ex vivo antibody-mediated cell sorting strategies. To overcome this limitation, we used murine myeloid progenitor cells immortalized via conditional overexpression of Hoxb8, a homeobox gene that functions to suppress the myeloid differentiation program (17) . We used Hoxb8 progenitors bearing fluorescent protein reporters for Ccr2 and Cx 3 cr1 expression as an experimental model to recapitulate the monocyte development continuum. Using this model to screen a small-molecule library, followed by confirmatory in vivo validation strategies, we identified a previously unrecognized role for the mTORC1 (mechanistic target of rapamycin complex 1)-S6K1 (S6 kinase 1)-Myc pathway in the regulation of terminal myeloid differentiation, thereby delineating a previously unknown pathway through which metabolism modulates immunity.
RESULTS

Dual-reporter ER-Hoxb8 myeloid progenitor cells model normal monocyte differentiation
Transduction of bone marrow progenitors with murine stem cell virus (MSCV) encoding an estrogen receptor-Hoxb8 fusion protein (ERHoxb8) results in the conditional expansion of myeloid progenitors capable of generating mature neutrophils and macrophages (18) . In the presence of -estradiol and stem cell factor (SCF), Hoxb8 functions to suppress myeloid differentiation, and these cells proliferate in the myeloid progenitor state. We evaluated the utility of this system to model normal monocyte development. ER-Hoxb8 progenitors are Lin S1B ). Monocytes are distinguished by the expression of M-CSF receptor (CD115). Undifferentiated ER-Hoxb8 cells resemble progenitor cells with a high nucleus-to-cytoplasm ratio and acquired monocyte-and macrophage-like morphology by day 4 and day 8 after estrogen withdrawal, respectively (Fig. 1A) .
To study the dynamics of monocyte development and maturation, we generated dual-reporter ER-Hoxb8 (DR-ER-Hoxb8) cells from Ccr2 RFP/+ Cx 3 cr1 GFP/+ knock-in mice (19) . DR-ER-Hoxb8 cells displayed low baseline red and green fluorescence ( fig. S1C ). Longitudinal differentiation analysis revealed the coordinated, sequential expression of Ccr2-RFP (red fluorescent protein), Ly6C, and Cx 3 cr1-GFP (green fluorescent protein) after the removal of -estradiol (Fig. 1B  and fig. S1D ). By day 4, monocytes acquired a Ly6C hi phenotype with gradual up-regulation of Cx 3 cr1-GFP. A rapid increase in Cx 3 cr1-GFP expression by day 6 was accompanied by declining Ly6C expression, illustrating a maturation continuum from Ly6C hi to Ly6C lo monocytes (Fig. 1, B and C) .
In addition to their normal morphology and surface marker expression, monocytes derived from ER-Hoxb8 cells also behaved as functional monocytes, as assayed by the production of proinflammatory cytokines and phagocytosis of Escherichia coli ( fig. S1E ). Neutralization of endogenous M-CSF showed minimal effects on the development of Ly6C hi monocytes but strongly inhibited the yield of Ly6C lo monocytes (fig. S1F), consistent with the requirement of M-CSF for monocyte maturation (20) . Correspondingly, the addition of exogenous M-CSF augmented the conversion of Ly6C hi to Ly6C lo monocytes ( fig. S1G ). These features mimicked the biology of sorted bone marrow CMPs that differentiated into monocytes with sequential expression of Ly6C and Cx 3 cr1, a process accelerated by M-CSF ( fig. S1H ).
An advantage of ER-Hoxb8 cells is that they are amenable to genome editing at the CMP stage using techniques such as CRISPR (clustered regularly interspaced short palindromic repeats)/Cas (CRISPR-associated protein). We generated ER-Hoxb8 cells from Cas9-EGFP (enhanced GFP) transgenic mice (21) and delivered guide RNAs (gRNAs) targeting EGFP or Ly6C via lentivirus. Protein expression of the targeted genes was markedly abrogated, as assessed by flow cytometry ( fig. S1I ), demonstrating effective genetic modification in ER-Hoxb8 cells using CRISPR/Cas technology. Together, these findings show that ER-Hoxb8 cells model the normal pattern of monocyte development, can easily be generated and expanded, and represent a convenient system in which to study murine monocyte ontogeny, particularly in dual-reporter cells expressing monocyte differentiation markers.
A kinase inhibitor screen in DR-ER-Hoxb8 cells identifies modulators of monocyte development
Given the predictable kinetics of DR-ER-Hoxb8 cell differentiation, we used this system to identify modulators of monocyte development Boxes indicate percentage of Ly6C hi monocytes. *P < 0.05 and **P < 0.01.
using a small-molecule library of 152 kinase inhibitors (table S1).  Inhibitors of mTOR potently suppressed the expression of Ly6C,  CD115, and Cx 3 cr1-GFP (Fig. 1, D and E, and table S2 ). Inhibition of other kinases involved in common signaling pathways (e.g., Janus kinases, nuclear factor B, c-Jun N-terminal kinases (JNK), protein kinase C, and extracellular signal-regulated kinases) had minimal effect on monocyte development (Fig. 1D) . Two distinct mTORCs have been characterized, with distinct biological functions (22) . Treatment of DR-ER-Hoxb8 cells with rapamycin, a prototypical partial inhibitor of mTORC1, delayed up-regulation of Ly6C and potently suppressed the expression of Cx 3 cr1 and CD115 (Fig. 1F and fig. S1J ). DR-ER-Hoxb8 cells differentiated in the presence of rapamycin were smaller and appeared less morphologically mature (Fig. 1G) . Consistent with the findings from DR-ER-Hoxb8 cells, rapamycin reduced spontaneous monocyte differentiation from sorted CMPs ( fig. S1K ).
To further investigate the role of mTORC1 in monocyte development, we generated ER-Hoxb8 cells with hemizygous deficiency of regulatory-associated protein of mTOR (Raptor), a critical component of mTORC1 but not of mTORC2 ( fig. S1L) (23) . Monocytic differentiation toward the Ly6C hi subset from Raptor +/ ER-Hoxb8 cells was profoundly impaired, and the effects were further amplified by blocking the residual mTORC1 activity with rapamycin ( Fig. 1H ).
mTORC1 is required for myeloid differentiation in vivo
To study the effects of mTORC1 ablation, we generated Raptor inducible knockout (iKO) mice (UBC-Cre/ERT2 Raptor fl/fl ). Baseline distribution of monocyte subsets was comparable in the bone marrow, spleen, and peripheral blood of untreated Raptor iKO and wild-type C57BL/6 mice ( fig. S2, A and B) . Five days after tamoxifen-induced deletion of Raptor alleles, a profound reduction of Ly6C hi monocytes, but not Ly6C lo monocytes, was seen in the peripheral blood of iKO mice ( Fig. 2A) . Both monocyte subsets were substantially depleted in Raptor iKO mice 14 days after tamoxifen, consistent with the expected development of patrolling from inflammatory monocytes. Neutrophils were also profoundly depleted during this time course (Fig. 2B) .
The depletion of peripheral blood myeloid cells in Raptor iKO mice might be explained by increased cell death or defective myeloid development. In contrast to the conditional deletion of the scaffold protein mtor (24) , which results in the loss of both mTORC1 signaling and mTORC2 signaling, increased apoptosis was not seen in the bone marrow, peripheral blood, or lymph nodes after the deletion of Raptor ( fig. S2C ). These results implicate disrupted myeloid development as the explanation for the marked reduction of peripheral myeloid cells in Raptor iKO mice. Raptor was effectively deleted in most of the bone marrow cells ( fig. S2D) , and the marrow pools of Ly6C hi monocytes and neutrophils were profoundly reduced in Raptor iKO mice (Fig. 2C) .
Next, we analyzed bone marrow progenitor populations to study the defect in myelopoiesis. Consistent with previous studies (25, 26) , c-kit + progenitors were increased in Raptor iKO mice despite a reduction of total bone marrow cellularity by ~50%, with the largest difference seen in GMPs and Lin − Sca-1 + c-kit + (LSK) cells, which contain HSCs and multipotent progenitors (Fig. 3, A to C, and fig.  S3A ). GMPs from Raptor iKO mice failed to generate MDPs and CMoPs on the basis of the established markers for these progenitor populations in the absence of substantial apoptosis, consistent with a developmental block at the GMP stage ( Fig. 3C and fig. S3B ). The proportion of common lymphoid progenitors and megakaryocyteerythrocyte progenitors (MEPs) were minimally affected in Raptor iKO mice (Fig. 3C) .
To assess whether the defect was intrinsic to progenitor cells, we examined in vitro differentiation of sorted bone marrow GMPs from Raptor fl/fl and iKO mice treated with tamoxifen. GMPs expressing Raptor spontaneously gave rise to Ly6C hi Cx 3 cr1 + monocytes when maintained in medium containing low levels of SCF, and the process was enhanced by the addition of M-CSF (Fig. 3D) . In contrast, Raptordeficient GMPs were unable to undergo normal monocyte differentiation under either condition. and Raptor iKO mice (n = 5 per group). *P < 0.05, **P < 0.01, and ***P < 0.001.
Because GMPs and MDPs are also intermediate stages of DC development, we tested whether DC populations are affected in Raptor iKO mice. Previous studies have demonstrated the inhibitory effects of rapamycin on DC development and function (27, 28) . Consistent with these findings, splenic CD8 + , CD8 − , and plasmacytoid DC subsets were all significantly reduced in Raptor iKO mice ( fig. S3C ).
As expected from previous reports (25) , Raptor iKO mice developed significant weight loss and ~50% mortality 2 weeks after tamoxifen treatment. To rule out the potential influence of poor health of 
Fold enrichment ) and neutrophils (Ly6G + ) in transplanted mice (n = 3 to 6 per group). (F) Quantification of bone marrow progenitor populations in transplanted mice with or without poly(I:C) treatment (n = 3 to 6 per group) (see Materials and Methods for fold enrichment calculation). For all panels, mice were treated with tamoxifen or poly(I:C) 2 weeks before analysis. *P < 0.05, **P < 0.01, and ***P < 0.001.
Raptor iKO mice and chronic peritonitis from tamoxifen treatment, we generated Mx-Cre Raptor fl/fl mice as a second model of inducible Raptor deletion. Mx-Cre Raptor mice showed near-complete gene deletion in hematopoietic cells after polyinosinic/polycytidylic acid [poly(I:C)] administration but did not display weight loss or early mortality (26) , possibly because of more limited activation of Cre-recombinase in nonhematopoietic tissues (29) . The key findings in Raptor iKO mice, including depletion of monocytes and neutrophils in the peripheral blood and bone marrow as well as the changes in progenitor cell populations, were all replicated in Mx-Cre Raptor mice ( fig. S3, D to F) . Consistent with the observation by Kalaitzidis et al. (26) , an accumulation of CD11b + Ly6C lo macrophages was seen in the bone marrow of Mx-Cre Raptor mice ( fig. S3F ).
To determine whether these findings are intrinsic to Raptor-deleted cells, we created mixed chimeras by transplanting wild-type CD45.1 and Mx-Cre Raptor (CD45.2) bone marrow cells into CD45.1 recipients. The proportion of peripheral blood monocytes and neutrophils in CD45.1 and CD45.2 fractions were equivalent after engraftment (Fig. 3E) . Consistent with the effects of Raptor deletion, administration of poly(I:C) depleted CD45.2 + myeloid ( Fig. 3E and fig. S3F ). Assessment of bone marrow cells confirmed the expansion of early progenitor cells after Raptor deletion but not of downstream MDPs and CMoPs despite the accumulation of GMPs (Fig. 3F) . Cell-extrinsic effects were unlikely because wild-type (CD45.1 + ) progenitor cells were not enriched after poly(I:C) treatment.
Myeloid-specific deletion of Raptor does not affect homeostasis of differentiated myeloid cells
To quantify mTORC1 activity during myelopoiesis, we measured the phosphorylation of target substrates 4E-BP1 (eukaryotic initiation factor 4E-binding protein 1) and S6K1 in various progenitor stages of monocyte development. The most prominent activity was found in the LSK fraction and decreased over the course of myeloid differentiation, reaching a nadir in Ly6C lo monocytes (Fig. 4A) . In contrast, mTORC2 activity reflected by phosphorylation of Akt at Ser 473 was relatively stable among progenitor cells.
We next determined whether mTORC1 signaling is required for the homeostasis of myeloid populations after lineage specification. To address this question, we sorted bone marrow GMPs and Ly6C hi monocytes from uninduced Raptor iKO mice and added tamoxifen to drive cre-mediated deletion in culture. Analysis after 4 days showed decreased expression of monocyte markers in tamoxifen-treated GMPs, but not in Ly6C hi monocytes ( fig. S4A ). In addition, we generated mice with myeloid-specific deletion of Raptor (LysMCre Raptor fl/fl ) and confirmed effective gene deletion in bone marrow monocytes and neutrophils ( fig. S4B ). Unlike the two models of iKO, LysMCre Raptor fl/fl mice did not show quantitative differences in monocyte and neutrophil populations in the peripheral blood, bone marrow, or spleen ( Fig. 4B and fig. S4C ) compared with controls. The distribution of bone marrow myeloid progenitor subsets was also largely comparable to controls (Fig. 4C and fig. S4D ). Therefore, mTORC1 signaling is required for myeloid development but not essential for the survival or distribution of differentiated myeloid cell subsets.
Enhanced mTORC1 activity promotes myeloid development
The tuberous sclerosis complex (Tsc) formed by the heterodimer of Tsc1 and Tsc2 proteins functions as a negative regulator of mTORC1 activity. We generated Mx-Cre Tsc2 fl/fl (Tsc2 KO) mice to determine whether mTORC1 overactivation promotes myelopoiesis. As expected, poly(I:C)-treated Tsc2 KO mice showed gene deletion in bone marrow cells, with heightened mTORC1 signaling, as illustrated by enhanced phosphorylation of ribosomal protein S6 and 4E-BP1 ( fig. S5, A and B) . The proportion of Ly6C hi monocytes, but not other lineages, was increased in the bone marrow of Tsc2 KO mice (Fig. 5A and fig. S5C ). These monocytes displayed greater surface expression of F4/80, CD11b, and FcRI (CD64) but lower expression of Cx 3 cr1 (Fig. 5A) , indicative of a macrophage-like phenotype. Examination of bone marrow progenitor populations revealed that LSK cells and GMPs were expanded after Tsc2 deletion, whereas the proportion of MDPs and that of CMoPs were unchanged ( fig. S5C) .
Whereas the absence of Tsc2 did not affect the distribution of monocyte subsets in the peripheral blood ( fig. S5D ), Tsc2 KO mice developed splenomegaly with a notable expansion of myeloid cells (Fig. 5B and fig. S5 , E and F). Ly6C hi monocytes and neutrophils were both increased fourfold, whereas lymphocytes were reduced. Cytospin of spleen cells from Tsc2 KO mice further revealed large macrophages that were not evident in controls (Fig. 5C ). We assessed whether extramedullary myelopoiesis was responsible for the myeloid skew in the spleen of Tsc2 KO mice. In control animals, c-kit + progenitor cells were rare (~0.3%), and most resembled MEPs by surface marker expression ( fig. S5, F and G) . Tsc2 KO mice displayed a 10-fold expansion of splenic Lin − c-kit + progenitor cells (~3%), with a prominent increase of GMPs (Fig. 5D) . Downstream monocyte progenitors, including MDPs and CMoPs, were found in the spleen of Tsc2 KO mice, but not in controls, illustrating the full continuum of monocyte progenitors normally seen in the bone marrow. To understand how excess mTORC1 signaling in progenitor cells directly influences myelopoiesis, we studied the differentiation of sorted LSK cells in vitro. When cultured in the presence of SCF alone to support stem cell proliferation, LSK cells from Tsc2 fl/fl control did not generate mature myeloid cells after 6 days, whereas those from Tsc2 KO mice spontaneously gave rise to CD11b + F4/80 + cells in the absence of additional growth factors (Fig. 5E) . Similarly, cytospin analysis revealed mostly immature cells expanded from control LSK cells and large macrophages from Tsc2 KO counterparts (Fig. 5F ). The accelerated myeloid differentiation in Tsc2-deficient LSK cells was entirely dependent on the mTORC1 pathway and effectively reversed by rapamycin treatment (fig. S5H ). In contrast, no difference was seen with inhibition of JNK, which is known to mediate mTORC1 -independent Tsc1 signaling (30) . The development of macrophages from Tsc2 KO LSK cells was not affected by neutralizing antibodies to M-CSF or GM-CSF ( fig. S5I ), and coculture with Tsc2 KO LSK cells did not affect the differentiation of wild-type LSK cells ( fig. S5J ), consistent with a cell-intrinsic mechanism.
The effect of mTORC1 on myelopoiesis is mediated by the S6K1 pathway Functionally, mTORC1 is a serine/threonine kinase that phosphorylates effector molecules involved in the regulation of protein synthesis, lipid synthesis, mitochondrial metabolism, and autophagy (22) . Phosphorylation of 4E-BP1 by mTORC1 leads to its dissociation from eIF4E (eukaryotic translation initiation factor 4E) to allow cap-dependent translation, whereas S6K1 is itself a serine/threonine kinase with critical roles in transcription, translation, and ribosomal protein synthesis (31) .
Rapamycin is a partial inhibitor of mTOR, with differential effects on S6K1 and 4E-BP1 phosphorylation depending on the cell type (32) . ER-Hoxb8 cells treated with rapamycin showed lasting reduction in S6 phosphorylation, a functional readout of S6K1 activity, whereas phospho-4E-BP1 level was unaffected ( fig. S6A) , suggesting that the S6K1 pathway is the likely target of mTORC1 that licenses myeloid development. To isolate the effects of S6K1 downstream of mTORC1, we used the ribosomal S6K inhibitor SL0101-01, which inhibited S6 phosphorylation without affecting 4E-BP1 phosphorylation in ER-Hoxb8 cells ( fig. S6B ). SL0101-01 was nearly equipotent to rapamycin in blocking monocyte development from isolated CMP and ER-Hoxb8 cells (Fig. 6A and fig. S6C ). The same pathway was responsible for the augmented myeloid development in Tsc2 KO mice, because SL0101-01 prevented the development of macrophages from Tsc2-deficient LSK cells (Fig. 6B) . The findings collectively show that steady-state myelopoiesis is controlled by mTORC1 via activation of the S6K1 pathway.
mTORC1 modulates myeloid development via regulation of c-Myc expression
To understand how mTORC1-S6K1 signaling modulates myelopoiesis, we performed transcriptomic analysis of GMPs from Raptordeficient, Tsc2-deficient, and control mice using RNA sequencing (RNA-seq). We focused the analysis on transcription factors that regulate myeloid cell development (Fig. 7A) , and statistically significant comparisons are provided in fig. S7A . Myc (c-Myc) was the only transcription factor reciprocally regulated by the deletion of Raptor and Tsc2. Increased Myc expression in Raptor-deficient GMPs and downregulation in Tsc2 KO GMPs were confirmed by quantitative polymerase chain reaction (qPCR) (Fig. 7B) .
Myc is an oncogene with a well-established role in controlling stem cell proliferation and differentiation through transcriptional regulation (33) . Overexpression of Myc is a hallmark of tumorigenesis (34) , and down-regulation of Myc is required for terminal myeloid differentiation (35) . To study whether mTORC1 signaling directly modulates Myc expression, we performed RNA-seq in ER-Hoxb8 cells differentiated in the presence of rapamycin or vehicle control. Supporting the data from Raptor-deficient GMPs, pharmacologic inhibition of mTORC1 resulted in up-regulation of Myc and decreased expression of Irf4, Irf5, and Irf8 (Fig. 7C) To study the expression kinetics of Myc and its gene targets during myelopoiesis, we incorporated undifferentiated and differentiated ER-Hoxb8 cells in hierarchical clustering analysis (Fig. 7F ). Myc and several of its target genes (Slc19a1, Ipo4, and Srm) clustered with transcripts that are normally diminished during differentiation, but the down-regulation is partially reversed by rapamycin (Cluster 1). This pattern suggests that intact mTORC1 signaling is required for proper down-regulation of the Myc transcription program during myelopoiesis. In contrast, Cluster 2 contains genes that are normally up-regulated during myeloid development but inhibited by rapamycin. Not surprisingly, this group was highlighted by markers of myeloid maturation including Cx 3 cr1, Irf8, Treml4, Mmp9, and members of the clec4 family (Fig. 7F) .
Consistent with mTORC1-mediated suppression of Myc expression, tamoxifen treatment of CMPs from untreated Raptor iKO mice showed up-regulated expression of Myc (Fig. 7G) . Moreover, CMPs expanded from Myc GFP reporter mice (37) showed enhanced GFP expression in the presence of mTORC1 or S6K1 inhibitor (Fig. 7H  and fig. S7G ). ER-Hoxb8 cells generated from Myc GFP mice similarly displayed enhanced GFP expression under these conditions (Fig. 7I  and fig. S7H ).
Last, we investigated whether concomitant inhibition of Myc can overcome the effects of mTORC1 blockade on myeloid development. ER-Hoxb8 cells differentiated in the presence of rapamycin were treated with 10058-F4, a small-molecule inhibitor of Myc (38) . The potent inhibitory effects of rapamycin on monocyte development were markedly inhibited by the addition of 10058-F4 (Fig. 7J) . Myc blockade improved the yield of Ly6C hi monocytes and enhanced the surface expression of monocyte markers. Treatment with 10058-F4 did not alter mTOR-S6K1 signaling (fig. S7I ). These data collectively show that mTORC1 modulates myeloid development and demonstrates an integral role for S6K1-mediated regulation of Myc expression in this process.
DISCUSSION
mTORCs regulate a spectrum of essential biological functions, including energy metabolism, growth factor signaling, immune cell activation, and cell proliferation (22, 39) . A balance of mTOR signaling appears to be essential for hematopoiesis, because either overactivation or disruption of this pathway can result in HSC exhaustion and bone marrow failure (24, 40) . We now identify a specific requirement for mTORC1 signaling in terminal myeloid development.
Our data indicate that mTORC1 signaling is critical for proper myeloid differentiation at or before the GMP stage, because downstream differentiation of inflammatory monocytes is profoundly impaired in Raptor iKO mice. Disruption of mTORC1 signaling via conditional deletion of Raptor resulted in an accumulation of GMPs that fail to generate MDPs and CMoPs. On the other hand, overactivation of mTORC1 via Tsc2 deletion augmented myeloid development with prominent extramedullary myelopoiesis. An expansion of HSCs in the bone marrow and spleen was previously described in Tsc1-deficient mice (41) , but myeloid cells appear to be reduced and monocytes were not studied in detail.
Although our study is focused on monocyte development, a myeloid differentiation defect at the GMP stage would predict defective development of neutrophils and DCs because they are also derived from GMPs. Consistent with previous studies using Raptor iKO and mTOR hypomorphic mice (25, 42) , we found marked reduction in bone marrow and peripheral blood neutrophil count in both models of inducible Raptor KO mice. DC development in vivo and in vitro was also substantially impaired in these mice. A differentiation defect at the progenitor level likely explains the negative effects of rapamycin on neutrophil and DC development in vitro (27, 28, 43) .
In vitro deletion of Raptor also led to impaired differentiation at the GMP level but had no detectable phenotype in sorted Ly6C hi monocytes. Correspondingly, mice with myeloid-specific deletion of Raptor (LysMCre) exhibited normal numbers of monocytes in the bone marrow and periphery, delimiting the requirement for mTORC1 to early myeloid development. Correspondingly, DC-specific deletion of Raptor (via CD11c-Cre) was shown not to deplete this lineage but rather to alter DC subset distribution (44) . These studies, together with the sequential depletion of Ly6C hi and Ly6C lo monocyte subsets we observe with Raptor iKO, implicate mTORC1 in development but not survival of myeloid cells under the conditions studied.
Our data further demonstrate a role of mTORC1-S6K1 signaling in the physiologic down-regulation of Myc transcription during myelopoiesis. This view contrasts with an earlier study that showed accelerated retinoid-induced granulocyte development by mTOR inhibition due to suppression of Myc (45) . Although the in vitro systems cannot be directly compared, our in vivo findings support a critical role of mTORC1 in myeloid development, and Myc expression was reciprocally up-regulated in Raptor iKO GMPs and decreased in Tsc2 KO GMPs. Furthermore, both mTORC1 and S6K inhibitors enhanced the expression of Myc and its target genes, and simultaneous inhibition of Myc ameliorated blockade of myeloid development.
Additional roles of mTORC1 in myelopoiesis remain possible, because mTORC1 may serve as a checkpoint for the availability of nutrients to support downstream myeloid differentiation and effector LSK cells differentiated in the presence of DMSO or SL0101-01 for 6 days. *P < 0.05 and **P < 0.01.
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function. Regulation of metabolic enzymes at both transcriptional and posttranscriptional levels has been observed during early stages of myeloid commitment (46, 47) . Although defects in glucose metabolism have been associated with congenital neutropenia (48) , such association with monocyte development has not been reported. Beyond a role in myeloid development, the mTORC1-S6K1 axis regulates many immune functions of differentiated myeloid cells (39) . Metabolic reprogramming by mTOR is required for the establishment of trained immunity in monocytes (49) . A regulatory role of mTOR and S6K1 in macrophages has been described in the context of Toll-like receptor signaling (50, 51) . Proinflammatory features associated with mTORC1 activation are also well described (39), because this pathway mediates the production and/or downstream effects of inflammatory cytokines, including interleukin-6 (IL-6), tumor necrosis factor-, and type I interferons (52, 53) . Our studies did not specifically address a role for mTORC2 in monocyte development. Conditional deletion of the mTORC2-specific component Rictor (rapamycin-insensitive companion of TOR) results in negligible effects in the setting of steady-state myelopoiesis (26, 54) . Unlike mTORC1, which is most active in early progenitor stages, mTORC2 Undi erentiated DMSO (day 4) ) appears to be more abundant in differentiated monocytes. Nevertheless, Rictor/ mTORC2 has a role in macrophage polarization, because myeloidspecific Rictor deficiency favors M1 skewing and enhances the inflammatory response to lipopolysaccharide (LPS) (55) .
As illustrated here, the ER-Hoxb8 system can be adapted to address a variety of questions surrounding early myelopoiesis and immune cell function. Immortalized murine myeloid progenitors can be created from the bone marrow, fetal liver, or embryonic stem cell populations, and a large number of cells can be generated and maintained with ease (18, 43) . Our work used the ER-Hoxb8 technology to study monocyte development via fluorescent reporters for the expression of Ccr2 and Cx 3 cr1, in a system amenable to small-molecule screening studies, conditional gene deletion, and genomic manipulations via CRISPR/Cas. Our findings confirm that results obtained using this system reliably predict the consequences of pathway disruption in vivo, thereby representing a powerful and flexible tool to understand myeloid biology.
Together, these results identify a previously unrecognized role for the mTORC1-S6K1-Myc axis in myeloid development. Disruption of this pathway abrogates development beyond the GMP stage, resulting in sequential depletion of circulating inflammatory and then patrolling monocytes, as well as neutrophils and DCs. By contrast, mTORC1 has no obligatory role in the survival of more mature cells, at least under basal conditions. These findings therefore establish the mTORC1-S6K1-Myc pathway as a critical checkpoint in terminal myeloid development.
MATERIALS AND METHODS
Study design
The goal of this study is to understand the role of mTORC1 in myeloid cell development. These studies were approved by the Institutional Animal Care and Use Committee of the Dana-Farber Cancer Institute and Brigham and Women's Hospital. Pilot experiments were performed to determine the number of animals needed to ensure statistical power. For all animal studies, each experimental group contained three to eight biological replicates. At least two biological replicates were performed for all in vitro experiments. No randomization or blinding was performed. All results were confirmed by two or more independent experiments.
Reagents
The Kinase Screening Library, other chemical inhibitors, and tamoxifen were purchased from Cayman Biochem. Recombinant IL-3 and SCF were purchased from PeproTech. Recombinant M-CSF was obtained from BioLegend. -Estradiol, 4-OH-tamoxifen, Tween 80, and PEG-400 (polyethylene glycol, molecular weight 400) were purchased from Sigma-Aldrich. Poly(I:C) was purchased from GE Healthcare Life Sciences. All antibodies used in this study and their sources are listed in mice were generated as previously described (19, 26, 56 
Conditional gene deletion
To induce deletion of Raptor, 6-week-old Raptor iKO mice were treated with tamoxifen [75 mg/kg per day, intraperitoneally (ip); solubilized in corn oil] for 3 consecutive days. To induce gene deletion in Mx1-Cre Raptor fl/fl and Mx1-Cre Tsc2 fl/fl mice, 6-week-old mice were given poly(I:C) (250 g, ip) every other day for three doses. Wild-type, floxed, and deleted alleles of Raptor were determined by conventional PCR using the following primers: GCGCAGTGAG-TACTGTTACCACCATG and GGGTACAGTATGTCAGCACAG. PCR analysis of Tsc2 alleles was performed using the following primers: AAGATTCCGGCTTGAAGGAG, CACTAGTCTAGCCTGACTCT, and GAGGACAAGCCAACATCCAT.
Bone marrow transplant
Recipient CD45.1 mice were irradiated using two split doses of 5 Gy and given 2 × 10 6 bone marrow mononuclear cells from CD45.1 mice and CD45. 
ER-Hoxb8 cell lines
Detailed protocols for construction of the retroviral vector encoding ER-Hoxb8, virus production, and transduction of bone marrow myeloid progenitor cells were described previously (18) . Briefly, bone marrow mononuclear cells were isolated and expanded in medium containing SCF and IL-3 for 48 hours. Cells were placed in 12-well plates precoated with human fibronectin (BD Biosciences) and spininfected with MSCV encoding ER-Hoxb8. Infected cells were cultured in RPMI medium containing SCF (20 ng/ml) and -estradiol (500 nM) for 2 days before the addition of G418 for selection. The cells were passaged to new plates with fresh medium every 3 to 4 days, and nonadherent immortalized cells grew out in ~3 weeks. Raptor +/ ER-Hoxb8 cells were generated using bone marrow cells from UbcCre-ERT2 Raptor +/fl mice, and Cre-recombinase was activated by the presence of estrogen in culture medium.
Genome editing by CRISPR/Cas
Hoxb8 cells with constitutive expression of Cas9-EGFP were derived from bone marrow cells of Cas9-EGFP transgenic mice (21) . Lentivirus encoding gRNA for EGFP and Ly6C was generated by the Broad Institute Genetic Perturbation Platform using the pXPR_003 vector. Sequences of gRNA are as follows: EGFP #1, GAAGTTCGAGGG-CGACACCC; EGFP #2, GGTGAACCGCATCGAGCTGA; Ly6C #1, GCTGGGCAGGAAGTCTCAAT; and Ly6C #2, AGCAATG-CAGAATCCATCAG. Cas9-EGFP Hoxb8 cells were spin-infected with gRNA lentivirus (multiplicity of infection of 10) and selected in puromycin for 1 week before differentiation and evaluation of gene expression.
Cell culture
Immortalized ER-Hoxb8 cells were cultured in "maintenance medium" with 10% fetal bovine serum (FBS), penicillin-streptomycin, 4% SCF-conditioned medium from stably transfected Chinese hamster ovary (CHO) cells [SCF (~20 ng/ml)], and -estradiol (500 nM) in RPMI 1640. Before differentiation, cells were pelleted by centrifugation and washed with phosphate-buffered saline (PBS) twice before resuspension in "differentiation medium" lacking -estradiol and containing 10% FBS, penicillin-streptomycin, and 0.4% SCF-conditioned medium (~2 ng/ml) in RPMI. For all experiments, day 0 was defined as the day of estrogen withdrawal. For Cre-recombinase activation in vitro, sorted bone marrow cells were cultured in complete RPMI containing 4-OH-tamoxifen (1 M) and SCF (10 ng/ml) for 3 days before differentiation with or without M-CSF (10 to 20 ng/ml) to generate monocytes. For measurement of intracellular cytokine production, LPS (1 g/ml) was added to ER-Hoxb8 cells on day 4 of differentiation in the presence of monensin (1:1000 dilution; BioLegend). Cells were collected after 16 hours for intracellular flow cytometry analysis. Phagocytosis assay was performed by coculturing ER-Hoxb8 cells (day 4 of differentiation) with fluorescein-conjugated E. coli (K-12 strain; Invitrogen) at a cell-to-target ratio of 1:100 for 30 min in RPMI medium. Cells were washed with PBS before FACS analysis.
Small-molecule screening and cytokine stimulation DR-ER-Hoxb8 cells were placed in 96-well plates (5 × 10 4 cells per well) in differentiation medium after estrogen removal. For small-molecule screening, individual compounds from the Cayman Kinase Screening Library were added to final concentrations of 10 and 1 M on day 0. For compounds that induced >50% cell death at the initial concentrations, further dilutions to 100, 10, and 1 nM were analyzed on repeat experiments. The expression of Ccr2-RFP, Cx 3 cr1-GFP, Ly6C, CD11b, and CD115 was measured by flow cytometry and expressed as percentage of mean fluorescence intensity (MFI) relative to dimethyl sulfoxide (DMSO)-treated controls.
Flow cytometry
Before surface staining, cells were incubated with anti-mouse CD16/32 (Fc block) for 10 min. Cells were then stained with an optimized amount of primary antibody or the appropriate isotype control for 15 min at room temperature before they were washed and resuspended in PBS supplemented with 0.1% bovine serum albumin (BSA). Intracellular staining was performed after surface staining using fixation and permeabilization buffer (eBioscience). Antibodies were added to cells after the permeabilization step, and samples were incubated for 1 hour on ice before analysis. Samples were acquired using a BectonDickinson FACSCanto II flow cytometer and analyzed with FCS Express 5 software (De Novo Software). In all FACS experiments, live cells were identified by size, and singlets were gated for analysis. Isotype control antibodies were used to establish gates for specific cell populations. Apoptosis assays were performed using the FITC Annexin V Apoptosis Detection Kit with PI (BioLegend), following the manufacturer's instructions.
Fluorescence-activated cell sorting
Bone marrow cells were isolated and stained with antibodies as described above. After lysis of erythrocytes in ACK buffer, cells were washed in PBS supplemented with 0.1% BSA and resuspended in complete RPMI. Bone marrow progenitors and myeloid cells were sorted using a BD FACSArias III cell sorter using defined gating strategies (Fig. 4 and fig. S2 ) (11, 12) . For RNA-seq, cells are sorted directly into RLT buffer. To culture stem/progenitor cells, sorted cells were cultured in RPMI with 10% FBS, penicillin-streptomycin, and 4% SCF-conditioned medium from stably transfected CHO cells.
RNA sequencing
RNA was extracted from sorted cells (1 × 10 4 ) using QIAGEN RNeasy Micro Kit. RNA-seq was performed using the Smart-seq2 platform (58, 59) . Smart-Seq2 libraries were prepared by the Broad Technology Labs and sequenced by the Broad Genomics Platform. Transcripts were quantified by the Broad Technology Labs computational pipeline using Cuffquant version 2.2.1 (60) . Transcription factors with known roles in myeloid development were selected for focused analysis (9, 61) . GSEA was performed using software v3.0 (Broad Institute) with the Molecular Signatures Database hallmark gene set collection (36, 62) . Hierarchical clustering analysis was performed using Cluster 3.0 (63), and heat maps were constructed using Java TreeView (64) .
Quantitative polymerase chain reaction
Total RNA was extracted from sorted cells using RNeasy Micro Kit, and complementary DNA was synthesized using the Superscript III First-Strand Synthesis Kit (Thermo Fisher). qPCR was performed using RT 2 SYBR Green Master Mix (QIAGEN) with a StepOne thermocycler (Thermo Fisher). Amplification conditions were as follows: 95°C for 10 min, followed by 45 cycles at 94°C for 15 s and 60°C for 1 min. After the final extension (72°C for 10 min), a melting curve analysis was performed to ensure specificity of the products. Gene expression was normalized to 18S RNA, and expression relative to the sample with the lowest expression was calculated using the 2 −Ct method. Primers used in this study were all described previously (65) , with the exception of Myc (forward, TTGAGGAAACGACGAGAA-CAG; reverse, AGCCAAGGTTGTGAGGTTAG).
Statistical analyses
For all bar graphs, bars represent means ± SEM. For quantitative variables, differences between two groups were analyzed by the unpaired Student's t test, and one-way analysis of variance (ANOVA) was used for comparison of multiple groups. All tests were two-sided, and a P value <0.05 was considered significant. Statistical analyses were performed using Prism 5.0 software (GraphPad).
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